NZ630644A - Methods for treating conditions associated with masp-2 dependent complement activation - Google Patents
Methods for treating conditions associated with masp-2 dependent complement activationInfo
- Publication number
- NZ630644A NZ630644A NZ630644A NZ63064414A NZ630644A NZ 630644 A NZ630644 A NZ 630644A NZ 630644 A NZ630644 A NZ 630644A NZ 63064414 A NZ63064414 A NZ 63064414A NZ 630644 A NZ630644 A NZ 630644A
- Authority
- NZ
- New Zealand
- Prior art keywords
- amino acid
- acid sequence
- heavy
- light
- chain cdr
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462020845P | 2014-07-03 | 2014-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ630644A true NZ630644A (en) | 2016-07-29 |
Family
ID=56506502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ630644A NZ630644A (en) | 2014-07-03 | 2014-09-10 | Methods for treating conditions associated with masp-2 dependent complement activation |
Country Status (1)
Country | Link |
---|---|
NZ (1) | NZ630644A (en) |
-
2014
- 2014-09-10 NZ NZ630644A patent/NZ630644A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550023A1 (en) | Humanized anti-tau antibodies | |
JP2018507220A5 (en) | ||
CO2018004532A2 (en) | Human anti-cd19 antibodies with high affinity | |
NZ631007A (en) | Anti-c5 antibodies having improved pharmacokinetics | |
PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
JP2017534577A5 (en) | ||
PE20161571A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USE | |
PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
MX2018014714A (en) | Compositions for inhibiting masp-2 dependent complement acitivation. | |
MX2021011489A (en) | Anti-claudin 18.2 antibody and application thereof. | |
AU2018290532A1 (en) | Immunotherapy for hepatocellular carcinoma | |
JP2017528476A5 (en) | ||
NZ629829A (en) | Anti-c5a antibodies and methods for using the antibodies | |
ZA202004701B (en) | Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof | |
AR102594A1 (en) | ANTI-IL-1b ANTIBODIES AND METHODS OF USE | |
MX341958B (en) | Antibodies against human il33r and uses thereof. | |
WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
PE20181051A1 (en) | ANTI-EPHA4 ANTIBODY | |
NZ599779A (en) | Compositions and methods for treating inflammatory disorders | |
MX2020007406A (en) | Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof. | |
JP2016530223A5 (en) | ||
JP2016527225A5 (en) | ||
WO2014172591A3 (en) | Humanized antibody against interleukin-20 and treatment for inflammatory diseases | |
WO2012139069A3 (en) | Compositions and methods for treating diseases of protein aggregation involving ic3b deposition | |
PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2019 BY COMPUTER PACKAGES INC Effective date: 20180818 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2020 BY COMPUTER PACKAGES INC Effective date: 20190820 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2021 BY COMPUTER PACKAGES INC Effective date: 20200818 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2022 BY COMPUTER PACKAGES INC Effective date: 20210817 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2023 BY COMPUTER PACKAGES INC Effective date: 20220817 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 SEP 2024 BY COMPUTER PACKAGES INC Effective date: 20230817 |